Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics.
Sign Up to like & getrecommendations! Published in 2023 at "Respirology"
DOI: 10.1111/resp.14506
Abstract: BACKGROUND AND OBJECTIVE Type 2 (T2) innate lymphoid cells (ILC2s) contribute to airway inflammation and disease in asthma. We hypothesize that ILC2s isolated from people with severe allergic and eosinophilic asthma would exhibit an enhanced… read more here.
Keywords: mepolizumab omalizumab; proliferation; asthma; treatment ... See more keywords
Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pharmacy Technology"
DOI: 10.1177/87551225221105749
Abstract: Objective: To review published literature for biologic treatment of nasal polyps. Data Sources: PubMed search performed on February 16, 2022, using search terms: biologics, benralizumab, dupilumab, mepolizumab, omalizumab, or reslizumab AND nasal polyps, nasal polyposis,… read more here.
Keywords: mepolizumab omalizumab; dupilumab mepolizumab; nasal polyps; nasal polyposis ... See more keywords
Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Asthma and Allergy"
DOI: 10.2147/jaa.s189676
Abstract: Purpose Patients with severe asthma are eligible for asthma-specific biologics as add-on therapies, such as mepolizumab and omalizumab, when optimized controller therapies are unable to control their symptoms. However, few real-world data are available to… read more here.
Keywords: patients prescribed; asthma; prescribed mepolizumab; mepolizumab omalizumab ... See more keywords